The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Sickle Cell Disease Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCAT 2024 | The importance of early intervention and closing the equity gap in SCD
Natasha Archer, MD, MPH, Harvard Medical School, Boston, MA, discusses the importance of early intervention in sickle cell disease (SCD), which can be achieved with routine newborn screening to identify individuals who require care. Dr Archer also discusses how the equity gap can be closed to ensure patients receive the treatment they need, highlighting that an emphasis must be placed on improving the transition from pediatric to adult care. This interview took place at the 19th Annual Scientific Conference of the Academy for Sickle Cell and Thalassaemia (ASCAT 2024) in London, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Haemonetics, Quilt Health.
